GLY-230
Phase 2- Indications
- Diabetic nephropathy
Company intelligence / Profile preview
Glycadia Pharmaceuticals
Philadelphia, Pennsylvania, United Statesglycadia.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Phase 2
01
Overview
Glycadia has completed Phase Ia and Phase Ib/IIa trials with its lead compound, GLY‑230, targeting vascular complications from diabetes. The company is preparing for further Phase II trials in patients at risk for diabetic nephropathy. Early data suggest possible benefit beyond glucose control, addressing a significant unmet need. Experimental work indicates potential application to Alzheimer’s disease as well.
- Therapeutic areas
- OphthalmologyCardiovascularNeurologyNephrology
- Modalities
- Small moleculesMonoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Glycadia Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycadia Pharmaceuticals.